Exploratory study evaluating the relevance of [68Ga]Ga-PentixaFor for initial staging and detection of minimal residual disease in multiple myeloma patients eligible for autologous stem cell transplantation less than 66 years included in the prospective IFM 2020-02.
This study, called IFM 2020-02, is for people under 66 living with multiple myeloma. Researchers are exploring a new scanning method, called [68Ga]Ga-PentixaFor, to see how good it is at finding the cancer when it's first diagnosed. They also want to see if it can help detect any remaining cancer cells after a stem cell transplant. This new scan will be compared to other imaging techniques, like FDG-PET/CT, to understand how accurately it can pinpoint cancer spots. The study also aims to see if the findings from these scans can predict how well patients will do over time. Your participation could help improve future diagnosis and treatment for multiple myeloma.
At a glance
What is this study about?
This study is investigating a new type of imaging scan called [68Ga]Ga-PentixaFor. It's being tested in people under the age of 66 who have recently been diagnosed with multiple myeloma and are planning to have a stem cell transplant. The main goal is to see how accurate this new scan is at finding the cancer when it's first discovered. They also want to find out if it can detect any tiny amounts of cancer left in the body after treatment, which is sometimes called 'minimal residual disease'.
The researchers will compare the results of the new [68Ga]Ga-PentixaFor scan with other common scans, like FDG-PET/CT, which uses a different tracing substance. By doing this comparison, they can understand if the new scan is better or equally good at identifying cancer spots. They're also interested in seeing if the information from these scans can give doctors clues about how well a patient might respond to treatment or how their illness might progress over time.
This study is important because finding clear and precise ways to locate multiple myeloma, both at the start and after treatment, can help doctors make better decisions about care. If this new scan proves effective, it could potentially lead to earlier and more personalised treatments for people with multiple myeloma, improving their outlook.
Key takeaways
- This study evaluates a new scan ([68Ga]Ga-PentixaFor) for multiple myeloma.
- It aims to improve detection of cancer at diagnosis and after treatment.
- Participants must be under 66 and eligible for a stem cell transplant.
- The study compares the new scan to existing imaging methods.
- Your health will be closely monitored during the study.
- Participation could help advance future multiple myeloma care.
Who may be eligible?
To be part of this study, you need to be an adult between the ages of 18 and 66. It doesn't matter if you are male or female; both are welcome to participate.
You must have multiple myeloma and be planning to have a treatment called an 'autologous stem cell transplant'. This is a specific type of treatment where you receive your own healthy stem cells back after chemotherapy.
Your doctor will check if you meet all the other detailed requirements for the study, which include your general health and specific aspects of your multiple myeloma, to ensure it's safe and appropriate for you to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you between 18 and 66 years old?
- Have you been diagnosed with multiple myeloma?
- Are you planning to have an autologous stem cell transplant?
- Are you generally in good enough health to participate in a clinical study?
- Are you able to attend appointments for imaging scans and monitoring?
What does participation involve?
If you join this study, you will undergo a new type of scan called a [68Ga]Ga-PentixaFor-PET. Before this scan, you'll have a small injection of a special substance called [68Ga]Ga-PentixaFor. Doctors will monitor your heart rate, oxygen levels, and blood pressure before the injection, and then 5-10 minutes and about an hour and 20 minutes after the injection to check your body's reaction.
You will also have other standard scans, such as FDG-PET scans, CT scans, or MRI scans as part of your usual care. The study mainly involves comparing the results from these different scans to see how well the new [68Ga]Ga-PentixaFor scan works.
The study will follow you over time to see how your health progresses. This will involve tracking your health status and treatment responses to understand the long-term impact. The specific total duration for your participation will be discussed in detail by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is multiple myeloma?
Multiple myeloma is a type of cancer that affects plasma cells, a kind of white blood cell found in the bone marrow.
What is a stem cell transplant?
An autologous stem cell transplant involves collecting your own healthy blood-forming cells, treating you with high-dose chemotherapy, and then giving your healthy cells back.
What is the new scan, [68Ga]Ga-PentixaFor-PET, for?
It's a special scan being tested to see how well it finds multiple myeloma in your body and if any cancer cells remain after treatment.
Will I receive new medicine in this study?
The study involves a new scanning substance ([68Ga]Ga-PentixaFor) and aims to compare scan results. It doesn't involve new medicines for treating your cancer, but instead focuses on diagnostic tools. Standard pain relievers like paracetamol may be mentioned for general use if needed.
Will I have extra tests if I join?
You will have the new [68Ga]Ga-PentixaFor scan, and possibly more detailed monitoring during and after the scan. Other routine scans you would usually have will also be part of the study's information gathering.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.